samedan logo

 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Axol Bioscience introduces multi-electrode array screening services for human iPSC-derived cells

Axol Bioscience


• Expansion of Axol Bioscience’s service offering for pre-clinical drug discovery
• New services combine the Company’s iPSC-derived human cells and electrophysiological expertise with Axion Biosystems’ Maestro Pro MEA platform

Cambridge, UK, 13 October 2020: Axol Bioscience (Axol), a biotechnology company specializing in the use of stem cell technology to manufacture disease-relevant cell-based assay systems to the drug discovery industry, today announced the expansion of its service offering, with the introduction of multi-electrode array (MEA) screening for human induced pluripotent stem cell (hiPSC)-derived cells. The new services have been developed to support pre-clinical research by optimizing hiPSC-derived cell culture, while providing high-quality electrophysiological data acquisition and analysis from physiologically relevant human cell models.

As part of the new services, Axol is incorporating the Maestro Pro, a market-leading MEA platform from Axion Biosystems (Axion). This will allow customers to benefit from Axol’s extensive catalog of hiPSC-derived cells and in-house electrophysiology expertise, in combination with Axion’s most advanced offering. The Maestro Pro enables continuous label-free and real-time data acquisition and analysis from 768 electrodes, in up to a 96wp format, allowing for a high-throughput of data.

Axol’s MEA screening service offering will include:
• recording of field action potentials from neurons and cardiomyocytes
• local extracellular action potential (LEAP) and contractility recordings from cardiomyocytes
• cell visualization and multiplexing for microscopy and calcium imaging assays
• targeted panel compound and new chemical entity (NCE) screening
• cardiotoxicity and neurotoxicity testing
• cell, co-culture and disease model validation
• long-term cell proliferation studies
• bespoke projects and pilot studies.

The launch of Axol’s services follows the recent appointment of Liam Taylor as CEO at Axol, and forms part of the Company’s strategy to grow its iPSC technologies, products and services.

Liam Taylor, CEO, Axol Bioscience, said:“At Axol, we have worked extremely hard to establish ourselves as the market-leading provider of neuroscience and cardio-based hiPSC-derived cells. As we grow, it's now time to also offer our considerable in-house expertise to the preclinical drug discovery market. As such, we are proud to announce our new MEA capability utilizing the industry-leading Axion Maestro Pro platform.”

For further information about Axol’s MEA screening services, please visit: https://www.axolbio.com/page/mea-services
phone +44 (0)1223 751051
email support@axolbio.com
web https://www.axolbio.com/
email Suite 3, The Science Village, Chesterford Research Park, Little Chesterford, Cambridgeshire, CB10 1XL, United Kingdom
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Agilent Laboratory Achieves Green Lab Certification

SANTA CLARA, Calif. June 21, 2022 – Agilent Technologies Inc. (NYSE: A) today announced that the company’s customer demonstration laboratory in Waldbronn, Germany has received the highest level of Green Lab Certification, the gold standard in laboratory sustainability best practices.
More info >>


White Papers

The Rare Disease Patients Experience

When planning a clinical trial for a rare disease, it is important to have a holistic understanding of your patient population. You want to be aware of where your patients are coming from, and what it is like to walk in their shoes. These patients need your trial just as much as you need them; even from the earliest stages, conceptualize your rare disease trial as an altruistic relationship between the patient population and your study.
More info >>

Industry Events

Connect in Pharma

14-15 September 2022, Plaexpo, Geneva, Switzerland

The new event driving innovation for pharma and biopharma businesses, Connect in Pharma will unite key players in Pharmaceutical and Biopharmaceutical packaging and production in Geneva on 14 – 15 September 2022.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement